CClinicalTrials.gg
CompletedNCT02574221Updated Oct 6, 2017

A Pilot Study to Evaluate a Molecular Method for Plaque

An interventional study of stannous fluoride toothpaste and cavity protection toothpaste in Plaque and Gingivitis, sponsored by Procter and Gamble. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-06.

Sponsored by Procter and Gamble · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to evaluate the sensitivity of the molecular method and its ability to split a stannous fluoride toothpaste versus a negative control.

02

Conditions studied

  • Plaque
  • Gingivitis

Browse trials for

03

In context

Gingivitis

590 studies on the registry are indexed under Gingivitis; 105 are open to participants now.

This study's enrollment of 60 is close to the median of 64 across 478 interventional studies indexed under Gingivitis.

Browse Gingivitis studies →

Lead sponsor

Procter and Gamble is the lead sponsor of 80 studies on the registry; none are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

In order to be included in the study, each subject must:

  • Provide written informed consent to participate in the study;
  • Be 18 years of age or older;
  • Agree not to participate in any other oral/dental product studies during the course of this study;
  • Agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed;
  • Agree to maintain their current oral hygiene routine between the Screening and Baseline Visit and not to add/change their oral care products during this time;
  • Agree to refrain from any form of non-specified oral hygiene during the treatment periods (after the Baseline Visit), including but not limited to the use of products such as floss or whitening products;
  • Agree to return for all scheduled visits and follow study procedures;
  • Must have at least 16 natural teeth;
  • Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study;
  • Agree to refrain from all oral hygiene for at least 12 hours prior to each visit;
  • Agree to refrain from eating, chewing gum, drinking and using tobacco for 4 hours prior to each visit;
  • Have at least 20 bleeding sites (sites with a score of 1 or 2 on the GBI index);
  • Have minimum 3 sampling sites with bleeding and pocket depth ≥3mm but not deeper than 4mm;
  • Have minimum 3 sampling sites without bleeding and with pocket depth ≤2mm.

Exclusion criteria

Exclusion Criteria:

Subjects are excluded from study participation where there is evidence of:

  • Have had a dental prophylaxis within 2 weeks of plaque sampling visits;
  • Have taken antibiotics or used anti-gingivitis / anti-bacterial oral care products such as chlorhexidine or Listerine within 2 weeks of plaque sampling visits;
  • Have rampant caries, open or untreated caries, or advanced periodontitis requiring prompt treatment;
  • Need an antibiotic prophylaxis prior to dental visits;
  • A history of hypersensitivity to oral care products containing stannous fluoride;
  • A history of hypersensitivity to dyes (from products containing food dyes);
  • Present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study; or
  • Are pregnant (Self-reported) or lactating.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    stannous fluoride toothpaste

    brush twice a day for 8 weeks

    Drug: stannous fluoride toothpaste

  • Sham comparator
    cavity protection toothpaste

    brush twice a day for 8 weeks

    Drug: cavity protection toothpaste

Interventions

  • Drugstannous fluoride toothpaste

    0.454% stannous fluoride toothpaste

  • Drugcavity protection toothpaste

    0.243% sodium fluoride toothpaste

06

What researchers measure

Primary outcomes

  1. plaque scores

    Time frame: baseline

  2. plaque scores

    Time frame: week 8

Secondary outcomes

  1. gingivitis score

    Time frame: baseline

  2. gingivitis score

    Time frame: week 8

07

Study locations

1 site
  • Salus Research
    Fort Wayne, Indiana 46825, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02574221
Lead sponsor
Procter and Gamble
Responsible party
Sponsor
First posted
Oct 12, 2015
Start date
Aug 2015
Primary completion
Oct 2015
Completion
Oct 2015
Last update
Oct 6, 2017

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion